Fiscal year 2023 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses PSTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PSTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mark Gergen | $611,667 | $0 | $1,442,285 | $1,413,936 | $336,420 | $0 | $13,710 | $3,818,018 |
| Chief Executive Officer, President and Chairman | ||||||||
| Kristin Yarema | 380,625 | 0 | 934,910 | 934,210 | 171,280 | 0 | 13,540 | 2,434,565 |
| President, Cell Therapy | ||||||||
| Brent Warner | 445,767 | 0 | 496,330 | 486,574 | 200,600 | 0 | 13,181 | 1,642,452 |
| President, Gene Therapy | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Mark Gergen | $3,818,018 | $4,369,452 | — | −551,434 |
| Kristin Yarema | 2,434,565 | — | — | — |
| Brent Warner | 1,642,452 | 2,879,028 | — | −1,236,576 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Brent Warner | RSU | 230,910 | — | $789,712 |
| Mark Gergen | RSU | 267,900 | — | 1,272,525 |
| Mark Gergen | Option | 280,855 | 4.75 | — |
| Mark Gergen | Option | 10,938 | 16 | — |
| Kristin Yarema | Option | 415,272 | 2.62 | — |
| Mark Gergen | Option | 99,750 | 9.15 | — |
| Brent Warner | Option | 242,457 | 3.42 | — |
| Mark Gergen | RSU | 269,586 | — | 1,442,285 |
| Mark Gergen | Option | 295,800 | 5.35 | — |
| Brent Warner | RSU | 92,772 | — | 496,330 |
| Kristin Yarema | RSU | 356,836 | — | 934,910 |
| Brent Warner | Option | 101,793 | 5.35 | — |
To assist in determining executive compensation, Aon and the Compensation Committee reviewed a peer group of publicly traded companies in the life sciences industry at a stage of development, market capitalization, and size comparable to the Company. The Compensation Committee believes that these companies are generally comparable to the Company and that the Company competes with these companies for executive talent.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Rafael G. AmadoIndependent · Compensation · Science and Technology Committee (Chair) | $31,667 | $108,468 | $108,037 | — | $0 | $248,172 |
| John P. SchmidIndependent · Lead Independent Director · Audit (Chair) · Nominating and Corporate Governance | 79,000 | 48,536 | 47,573 | — | 0 | 175,109 |
| Cynthia CollinsIndependent · Audit · Compensation (Chair) · Science and Technology Committee | 59,167 | 48,536 | 47,573 | — | 0 | 155,276 |
| Charles M. BaumIndependent · Audit · Compensation · Science and Technology Committee | 54,167 | 48,536 | 47,573 | — | 0 | 150,276 |
| Marcea B. LloydIndependent · Compensation · Nominating and Corporate Governance (Chair) | 53,000 | 48,536 | 47,573 | — | 0 | 149,109 |
| Luke CorningIndependent · Nominating and Corporate Governance | 44,000 | 48,536 | 47,573 | — | 0 | 140,109 |
| Kristin YaremaEmployee director · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Eric OstertagNot independent · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Mark J. GergenEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $275,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $321,001 |
| Equity awards (grant-date value) | $351,148 |
| All other compensation | $0 |
| Total cost of the board | $672,149 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Poseida Therapeutics | 2023 | Mark Gergen | $611,667 | $1,442,285 | $1,413,936 | $336,420 | $3,818,018 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mark Gergen | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 3,818,018. Filing ↗machine: span 428155–428164 |
| 2 | Section 01, Kristin Yarema | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 2,434,565. Filing ↗machine: r4 · c25 · span 441659–441668 |
| 3 | Section 01, Brent Warner | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Summary Compensation Table for Fiscal Year 2023”. As printed: 1,642,452. Filing ↗machine: r6 · c25 · span 453155–453164 |
| 4 | Section 08, Rafael G. Amado | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Director Compensation”. As printed: 248,172. Filing ↗machine: t17 · r2 · c15 · span 655004–655011 |
| 5 | Section 08, John P. Schmid | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Director Compensation”. As printed: 175,109. Filing ↗machine: t17 · r7 · c15 · span 676090–676097 |
| 6 | Section 08, Cynthia Collins | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Director Compensation”. As printed: 155,276. Filing ↗machine: t17 · r4 · c15 · span 663417–663424 |
| 7 | Section 08, Charles M. Baum | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Director Compensation”. As printed: 150,276. Filing ↗machine: t17 · r3 · c15 · span 659217–659224 |
| 8 | Section 08, Marcea B. Lloyd | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Director Compensation”. As printed: 149,109. Filing ↗machine: t17 · r6 · c15 · span 671877–671884 |
| 9 | Section 08, Luke Corning | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Director Compensation”. As printed: 140,109. Filing ↗machine: t17 · r5 · c15 · span 667614–667621 |
| 10 | Section 08, Kristin Yarema | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 08, Eric Ostertag | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 08, Mark J. Gergen | DEF 14A | 2024-04-25 | 0000950170-24-048291 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 14 | Section 09b board cost (computed) | Computed | — | computed | Cash 321,001 + equity 351,148 + all other 0 = 672,149, summed across the director compensation table rows.machine: formula: Σ = 672,149 |
| 15 | Poseida Therapeutics (subject), Section 10b CEO total | DEF 14A | 2024-04-25 | 0000950170-24-048291 | CEO total compensation as printed in Poseida Therapeutics's own proxy. As printed: 3,818,018. Filing ↗machine: span 428155–428164 |